

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):
September 24, 2003

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

0-28637
(Commission File Number)

58-2301143
(I.R.S. Employer Identification
Number)

**111 Barclay Boulevard
Lincolnshire, Illinois**
(Address of Principal Executive Offices)

60069
(Zip Code)

(847) 478-0500
(Registrant's Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, If Changed Since Last Report)

Item 5. Other Events

On September 25, 2003, BioSante Pharmaceuticals, Inc. issued a press release, a copy of which is attached as an exhibit hereto, announcing that on the evening of September 24, 2003, BioSante Pharmaceuticals, Inc. received a notice that it was approved for listing on the American Stock Exchange and expects that its common stock will begin trading on the American Stock Exchange under the ticker symbol "BPA" at the opening of trading on October 1, 2003. Our common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol "BISP" until the closing of trading on September 30, 2003.

Item 7. Financial Statements and Exhibits.

- (a) Financial Statements of Businesses Acquired.

Not Applicable

- (b) Pro Forma Financial Information.

Not Applicable

- (c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
Ex. 99.1	Press Release dated September 25, 2003 (filed herewith electronically).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Phillip B. Donenberg
Phillip B. Donenberg
Chief Financial Officer, Treasurer and Secretary

BIOSANTE PHARMACEUTICALS, INC.

FORM 8-K

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>	<u>Method of Filing</u>
99.1	Press Release of BioSante Pharmaceuticals, Inc. issued September 25, 2003.	Filed herewith electronically



BioSante Pharmaceuticals, Inc.
 111 Barclay Boulevard
 Lincolnshire, Illinois 60069
www.biosantepharma.com

FOR IMMEDIATE RELEASE

Contact: Phil Donenberg
 847/478-0500 ext. 101

**BioSante Pharmaceuticals Approved for Listing
 On the American Stock Exchange**

Lincolnshire, IL (September 25, 2003) — BioSante Pharmaceuticals, Inc. (OTCBB: BISP) today announced that its common stock has been approved for listing on the American Stock Exchange® (“Amex®”). BioSante’s common stock is expected to commence trading on the Amex under the symbol “BPA” on October 1, 2003.

“Our listing on the Amex is another significant milestone in the development of our company,” said Stephen M. Simes, president and chief executive officer of BioSante. “The listing provides greater visibility for BioSante, and we believe it will expand the base of investors who purchase BioSante stock, providing additional liquidity and value for our stockholders.”

September 30, 2003 is the last trading day for BioSante common stock on the Over the Counter Bulletin Board. A listing with Amex means that BioSante is no longer required to comply with certain restrictions inherent in being traded on the OTCBB, including restrictions imposed by certain brokerage houses on the ability of their brokers to solicit orders or recommend the purchase of stocks that trade on the OTCBB.

About BioSante Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. The company also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins such as insulin. Additional information is available online at www.biosantepharma.com.

About the Amex

The American Stock Exchange is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRSSM. In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 123 ETFs. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit www.amex.com.

1

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes,” or “plans,” or comparable terminology, are forward-looking statements. An example of a forward-looking statement in this news release is the statement regarding whether the listing of BioSante’s common stock on the American Stock Exchange will expand the base of investors who purchase BioSante’s stock and provide additional liquidity and value to BioSante’s stockholders. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements are the difficulties of small cap companies despite national stock exchange listings to expand the base of their investors and provide additional liquidity and value to BioSante’s stockholders, and other factors identified and discussed from time to time in BioSante’s filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante’s Form 10-KSB, which discussion also is incorporated herein by reference.

###

2
